Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9557008 | 0.92 | DPP4 (0.50) | DPP4DPP7 | |
| SCHEMBL9556740 | 0.91 | NPC1 (0.51) | NPC1TDP1NAAAFKBP1APOLB | |
| Hydrochloric Acid SCHEMBL9557197 | 0.90 | DPP4 (0.49) | DPP4DPP7 | |
| SCHEMBL9557266 | 0.85 | DPP4 (0.62) | DPP4DPP7NPC1TDP1NAAA | |
| SCHEMBL4315286 | 0.85 | DPP4 (0.51) | DPP4DPP7 | |
| SCHEMBL3808771 | 0.85 | DPP4 (0.65) | DPP4NPC1TDP1NAAAFKBP1A | |
| SCHEMBL9557012 | 0.82 | SIGMAR1 (0.45) | NPC1TDP1NAAAFKBP1A | |
| SCHEMBL9556845 | 0.82 | FKBP1A (0.64) | NPC1FKBP1APOLB | |
| SCHEMBL22851911 | 0.80 | NPC1 (0.70) | NPC1TDP1NAAAPOLB | |
| SCHEMBL4398017 | 0.80 | NPC1 (0.65) | NPC1TDP1NAAAFKBP1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470855-B2 | Dual-use peptidase inhibitors as prodrugs for a therapy of inflammatory and other diseases | IMTM GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| US-20090124667-A1 | Novel Dual-Use Peptidase Inhibitors as Prodrugs for a Therapy of Inflammatory and Other Diseases | IMTM GMBH (DE) | 2009-05-14 | — | — | US | disclosed |
| US-5198450-A | PHENYLALKANOYLAMINE DERIVATIVES, PROCESS FOR PREPARING THE SAME, AND USAGE OF THE SAME | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-30 | — | — | US | disclosed |
| EP-0424528-A1 | PHENYLALKANOYLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124667-A1 | Novel Dual-Use Peptidase Inhibitors as Prodrugs for a Therapy of Inflammatory and Other Diseases | CTSL, DAO, PEPD | DPP4 214/4885DPP7 34/4885NPC1 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.